HC Wainwright Reaffirms “Buy” Rating for ASLAN Pharmaceuticals (NASDAQ:ASLN)

ASLAN Pharmaceuticals (NASDAQ:ASLN)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $9.00 target price on the stock.

Separately, Piper Sandler reiterated an “overweight” rating and set a $10.00 price target (down from $15.00) on shares of ASLAN Pharmaceuticals in a research note on Wednesday, March 13th.

ASLAN Pharmaceuticals Price Performance

NASDAQ ASLN opened at $0.46 on Tuesday. The firm’s 50-day moving average is $0.61 and its two-hundred day moving average is $0.73. ASLAN Pharmaceuticals has a 12 month low of $0.39 and a 12 month high of $4.69. The stock has a market capitalization of $7.44 million, a P/E ratio of -0.17 and a beta of 1.45.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last issued its quarterly earnings results on Friday, April 12th. The company reported ($0.78) earnings per share (EPS) for the quarter. As a group, analysts anticipate that ASLAN Pharmaceuticals will post -2.68 EPS for the current year.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.